888214-21-9

Basic information

• Product Name: BENZENE, 2-BROMO-1-IODO-3-METHYL-
• Synonyms: BENZENE, 2-BROMO-1-IODO-3-METHYL-
• CAS NO: 888214-21-9
• Molecular Formula: C7H6BrI
• Molecular Weight: 296.928
• Mol File: 888214-21-9.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 268.6±20.0 °C(Predicted)
• Appearance: /
• Density: 2.062±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: BENZENE, 2-BROMO-1-IODO-3-METHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: BENZENE, 2-BROMO-1-IODO-3-METHYL-(888214-21-9)
• EPA Substance Registry System: BENZENE, 2-BROMO-1-IODO-3-METHYL-(888214-21-9)

Safety Data

• Hazardous Substances Data: 888214-21-9(Hazardous Substances Data)

Usage

General Description

2-Bromo-1-iodo-3-methylbenzene, also known as 1-Bromo-2-iodo-3-methylbenzene, is a chemical compound that belongs to the group of aromatic compounds. It is a colorless liquid with a strong odor and is insoluble in water. This chemical is mainly used in the production of pharmaceuticals, dyes, and organic compounds. It is also utilized as an intermediate in the synthesis of other chemical compounds. However, 2-Bromo-1-iodo-3-methylbenzene is known to be hazardous to human health and the environment, as it is classified as a potential mutagen and may cause irritation to the respiratory system and skin upon exposure. Therefore, it requires careful handling and proper disposal.

Upstream product

• 54879-20-8 2-bromo-3-methylaniline 
• 1313498-37-1 tert-butyl ((2H-spiro[benzofuran-3,4'-piperidin]-5-yl)methyl)carbamate 
• 625-95-6 3-Iodotoluene 
• 41085-43-2 2-bromo-3-nitrotoluene 
• 108-44-1 1-amino-3-methylbenzene 
• 570-24-1 2-Methyl-6-nitroaniline 

Relevant articles and documents

Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors

Four series of molecular hybrids (37 final products) of neo-tanshinlactone, a natural product extracted from Salvia miltiorrhiza Bunge, and known PD-1/PD-L1 interaction inhibitors were prepared as possible chemotherapeutic agents against triple negative breast cancer. Screening using a homogenous time-resolved fluorescence method resulted in three lead compounds (MZ52 IC50 74 ± 4 nM; MZ58 IC50 134 ± 17 nM; MZ61 IC50 225 ± 19 nM). With less T cell cytotoxicity and effects in activating CD8+ T cells in a T cell proliferation assay and a functionality experiment, MZ58 was selected as the best candidate for animal experiments. MZ58 exhibited antitumor effects in a subcutaneous transplantation tumor model as well as effects in reducing T cell exhaustion. In conclusion, after in vivo and in vitro experiments, we successfully acquired an effective candidate (MZ58) showing antitumor effects with low cytotoxicity toward T cells as well as the ability to activate CD8+ T cells and reduce T cell exhaustion.

Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy in Vivo

Two series of novel o-(biphenyl-3-ylmethoxy)nitrophenyl compounds (A1-31 and B1-17) were designed as programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) inhibitors. All compounds showed significant inhibitory activity with IC50 values ranging from 2.7 to 87.4 nM except compound A17, and compound B2 displayed the best activity. Further experiments showed that B2 bound to the PD-L1 protein without obvious toxicity in Lewis lung carcinoma (LLC) cells. Furthermore, B2 significantly promoted interferon-gamma secretion in a dose-dependent manner in vitro and in vivo. Especially, B2 exhibited potent in vivo anticancer efficacy in an LLC-bearing allograft mouse model at a low dose of 5 mg/kg, which was more active than BMS-1018 (tumor growth inhibition rate: 48.5% vs 17.8%). A panel of immunohistochemistry and flow cytometry assays demonstrated that B2 effectively counteracted PD-1-induced immunosuppression in the tumor microenvironment, thereby triggering antitumor immunity. These results indicate that B2 is a promising PD-1/PD-L1 inhibitor worthy of further development.

Nitrophenyl ether compounds, and preparation methods, pharmaceutical compositions and application thereof

The invention discloses nitrophenyl ether compounds, and preparation methods, pharmaceutical compositions and application thereof, belonging to the field of medicines. The invention particularly relates to the nitrophenyl ether compounds with structural c